GLP-1 Drugs: Potential Beyond Diabetes and Obesity
Recent research indicates GLP-1 drugs, widely used for obesity and type 2 diabetes, may extend lifespan. A study by the University of California, Berkeley, published in Nature on September 2, has found promising results in this regard.
Study Insights
Researchers administered semaglutide, a GLP-1 receptor agonist, to female mice. This treatment extended their lifespan, alleviating some negative effects of aging. Danica Chen, a study author from UC Berkeley, stated these findings could broaden the use of GLP-1 medicines to promote healthy aging and longevity.
GLP-1 drugs, known as Ozempic and Wegovy, reduce appetite and stabilize blood sugar by mimicking fullness-promoting hormones. Their popularity in treating type 2 diabetes and obesity has grown, with one in eight Americans using them as of March 2026, according to Statista. This increase correlates with declining U.S. obesity rates, although multiple factors contribute to this trend.
What the Study Found
The study involved daily semaglutide injections in 20-month-old female mice. Results showed an increase in lifespan from 742 days (median of control group) to 834 days.
With semaglutide, mice experienced a 24% reduction in appetite and decrease in body and tissue weight. Chen noted improvements in physiological functions, attenuation of aging markers, and modulation of nutrient sensors and genetic aging regulators.
“Improved physiological function, attenuated hallmarks of aging, and modulated nutrient sensors and conserved genetic regulators of aging.” – Danica Chen
Expert Opinion
While the findings are promising, experts urge caution. Richard DiMarchi, a chemistry professor at Indiana University, noted these results align with expectations amid a growing interest in peptide therapeutics. He advises tempered enthusiasm, stressing the complexity of translating these findings to humans and emphasizing the importance of safety.
Randy Seeley of the University of Michigan highlighted data showing these drugs reduce all-cause mortality, suggesting longevity benefits. However, the complexity of translating animal results to humans remains a challenge.
Beyond Calorie Reduction
Chen suggested calorie reduction may partly explain lifespan extension, but acknowledged other influencing factors require further study. Seeley mentioned potential cardiovascular health impacts. Initially, concerns arose over increased heart rates and cardiovascular event risks. However, reduced cardiovascular risk has consistently been observed with various GLP-1 agonists.
Seeley also proposed ‘anti-inflammatory’ effects might contribute, though mechanisms remain unclear. Questions linger about the drugs’ influence on immune cells, metabolic fuel usage, and brain interaction.